Variable name;level;Overall;Yes;No;p;test
;n;1357;262;1095;;
Age;[0 -40);801;258 (32.2);543 (67.8);<0.001;
;40+;554;4 (0.7);550 (99.3);;
Age (mean);;38.7 [34.9, 41.6];32.8 [30.0, 35.5];40.0 [36.9, 42.0];<0.001;nonnorm
Number of children;0;373;177 (47.5);196 (52.5);<0.001;
;1;279;53 (19);226 (81);;
;More than 1;705;32 (4.5);673 (95.5);;
BMI;<18.5;79;16 (20.3);63 (79.7);0.035;
;25-29.9;257;46 (17.9);211 (82.1);;
;>=30;107;12 (11.2);95 (88.8);;
;18.5-24.9;807;181 (22.4);626 (77.6);;
BMI (mean);;22.6 [20.5, 25.5];22.0 [20.3, 24.5];22.7 [20.6, 25.8];0.005;nonnorm
Treatment center;Curie Paris;818;168 (20.5);650 (79.5);NaN;
;Curie St Cloud;538;94 (17.5);444 (82.5);;
;Others;0;0 (NaN);0 (NaN);;
Genetic Analysis;No;656;55 (8.4);601 (91.6);<0.001;
;Yes;701;207 (29.5);494 (70.5);;
Hereditary predisposition;No;547;159 (29.1);388 (70.9);0.441;
;Yes;140;46 (32.9);94 (67.1);;
Inflammatory BC;No;1338;260 (19.4);1078 (80.6);0.557;
;Yes;18;2 (11.1);16 (88.9);;
Clinical Tumor size (mm);;30.3 (21.7);32.0 (20.2);29.9 (22.1);0.167;
Clinical N stage (TNM);N0;854;165 (19.3);689 (80.7);0.989;
;N1-N2-N3;492;96 (19.5);396 (80.5);;
SBR grade;Grade I-II;586;107 (18.3);479 (81.7);0.394;
;Grade III;760;154 (20.3);606 (79.7);;
Histological type;NST;1265;249 (19.7);1016 (80.3);0.295;
;Lobular;54;6 (11.1);48 (88.9);;
;Others;36;7 (19.4);29 (80.6);;
Neoajuvant chemotherapy;No;744;118 (15.9);626 (84.1);<0.001;
;Yes;612;144 (23.5);468 (76.5);;
Chemotherapy setting;NAC;611;144 (23.6);467 (76.4);NaN;
;Adjuvant;744;118 (15.9);626 (84.1);;
;NAC and adjuvant;0;0 (NaN);0 (NaN);;
;Chemotherapy without surgery;1;0 (0);1 (100);;
;No;0;0 (NaN);0 (NaN);;
Fertility preservation discussion;No;909;3 (0.3);906 (99.7);<0.001;
;Yes;447;259 (57.9);188 (42.1);;
